Collaborations

Our collaborators are more than simply partners in drug discovery and development. They are thought leaders and teammates who work with us to solve global health threats.

EBANGA™

Ridgeback would like to acknowledge and thank our collaborators on the EBANGA™ (ansuvimab-zykl, mAb114) development program:

  • Biomedical Advanced Research and Development Authority (BARDA)
  • U.S. Department of Health and Human Services (HHS)
  • National Institute for Allergy & Infectious Diseases (NIAID)
  • National Institutes of Health (NIH)
  • Office of the Assistant Secretary for Preparedness and Response (ASPR)
  • The Vaccine Research Center
  • Institut National de Recherche Biomédicale de Kinshasa, République Démocratique du Congo
  • The Vaccine Clinical Materials Program (VCMP); Frederick National Laboratory for Cancer Research; sponsored by the National Cancer Institute (NCI);
  • World Health Organization (WHO)
  • The Alliance for International Medical Action (ALIMA)
  • Médecins Sans Frontières (MSF)
  • International Medical Corps (IMC)
  • Samaritan's Purse

Lagevrio (molnupiravir)

Ridgeback would like to acknowledge and thank our collaborators on the Lagevrio (molnupiravir; EIDD-2801) development program:

  • Emory University
  • DRIVE
  • Merck & Co
  • AGILE network